NASDAQ:GLSI Greenwich LifeSciences Q2 2025 Earnings Report $16.92 +1.37 (+8.81%) As of 08/12/2026 04:00 PM Eastern ProfileEarnings HistoryForecast Greenwich LifeSciences EPS ResultsActual EPS-$0.30Consensus EPS -$0.24Beat/MissMissed by -$0.06One Year Ago EPSN/AGreenwich LifeSciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AGreenwich LifeSciences Announcement DetailsQuarterQ2 2025Date8/14/2025TimeBefore Market OpensConference Call DateThursday, August 14, 2025Conference Call Time8:00AM ETConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Greenwich LifeSciences Earnings HeadlinesGreenwich LifeSciences Extends Insider and Pre-IPO Share Lock-Up to January 31, 2027August 10 at 6:31 AM | quiverquant.comQGreenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027August 10 at 6:00 AM | globenewswire.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it. | Banyan Hill Publishing (Ad)Greenwich LifeSciences Announces UK Regulatory Approval to Expand Phase III FLAMINGO-01 Breast Cancer TrialJuly 22, 2026 | quiverquant.comQGreenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United KingdomJuly 22, 2026 | globenewswire.comGreenwich LifeSciences Updates FLAMINGO-01 Phase III Trial Design, Enrollment and Financial OutlookJuly 20, 2026 | quiverquant.comQSee More Greenwich LifeSciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Greenwich LifeSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Greenwich LifeSciences and other key companies, straight to your email. Email Address About Greenwich LifeSciencesGreenwich LifeSciences (NASDAQ:GLSI) (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies. Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States. The company leverages proprietary technologies to identify immune-modulating compounds and works with contract research organizations to support its preclinical and clinical programs. Greenwich LifeSciences pursues strategic collaborations and licensing arrangements to expand its scientific expertise and accelerate the progress of its therapeutic candidates. With a focus on unmet medical needs in oncology and inflammatory disorders, the company aims to bring first-in-class or best-in-class treatments to patients through disciplined clinical development and regulatory strategies.View Greenwich LifeSciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not DemandCoreWeave's $129 Billion AI Backlog Changes the Bull CaseGE Vernova’s AI Power Boom Faces a Profit TestCardinal Health Earnings: Can Perfection Get Priced In Twice?Legacy Jet Builders Stall While Embraer Accelerates to New HighsFastly’s Q2 Rally Shows Investors Are Buying the Edge AI TurnaroundA Westinghouse IPO Could Reset the Nuclear Stock Conversation Upcoming Earnings BHP Group (8/17/2026)Palo Alto Networks (8/17/2026)Home Depot (8/18/2026)Medtronic (8/18/2026)Keysight Technologies (8/18/2026)Lowe's Companies (8/19/2026)TJX Companies (8/19/2026)Target (8/19/2026)Analog Devices (8/19/2026)NetEase (8/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
